Appendix 1

Author Relationships With Industry and Other Entities (Relevant)—2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

Committee MemberEmployer/TitleConsultantSpeaker's BureauOwnership/ Partnership/ PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert WitnessVoting Recusals by Section Number
Bernard J. Gersh, Co-ChairMayo Clinic—Professor of Medicine
  • Abbott Laboratories

  • AstraZeneca

  • Boston Scientific

  • Bristol-Myers Squibb

NoneNone
  • Amorcyte (DSMB)

  • CV Therapeutics

None
  • 6.2.2.6

  • 6.2.3

  • 6.3.2

  • 6.3.2.4

Barry J. Maron, Co-ChairMinneapolis Heart Institute Foundation—Director, Hypertrophic Cardiomyopathy Center
  • GeneDx

NoneNone
  • Medtronic

NoneNone
  • 5.1

  • 6.3.2

  • 6.3.2.4

Robert O. BonowNorthwestern University Feinberg School of Medicine—Goldberg Distinguished Professor of Medicine; Chief, Division of CardiologyNoneNoneNoneNoneNoneNoneNone
Joseph A. DearaniMayo Clinic—Professor of SurgeryNoneNoneNoneNoneNoneNoneNone
Michael A. FiferMassachusetts General Hospital—Director, Hypertrophic Cardiomyopathy ProgramNoneNoneNone
  • Merck

NoneNone6.2.1
Mark S. LinkTufts Medical Center—Professor of MedicineNone
  • Medtronic

  • Guidant

None
  • Guidant

None
  • Plaintiff, wrongful death secondary electrocution, 2007–2009

  • Defendant, postoperative valve replacement management, 2007–2010

  • 6.2.2.6

  • 6.3.2

  • 6.3.2.4

Srihari S. NaiduWinthrop University Hospital—Director, Cardiac Catheterization Laboratory; Director, Hypertrophic Cardiomyopathy CenterNone
  • Abbott Vascular

  • Cordis

  • Medtronic

NoneNoneNoneNone
  • 6.2.2.6

  • 6.3.2

  • 6.3.2.4

Rick A. NishimuraMayo Clinic—Consultant in CardiologyNoneNoneNoneNoneNoneNoneNone
Steve R. OmmenMayo Clinic—Professor of MedicineNoneNoneNoneNoneNoneNoneNone
Harry RakowskiToronto General Hospital, University Health Network—Director, Hypertrophic Cardiomyopathy Center; Wigle Chair for HCM Research; Professor of Medicine, University of TorontoNoneNoneNone
  • Medtronic Valve Device (DSMB)

NoneNoneNone
Christine E. SeidmanHoward Hughes Medical Institute; Harvard Medical School/Brigham and Women's Hospital—Investigator; T.W. Smith Professor of Medicine and GeneticsNoneNoneNoneNoneNoneNoneNone
Jeffrey A. TowbinCincinnati Children's Hospital—Executive Co-Director, The Heart Institute; Professor and Chief, Pediatric CardiologyNoneNoneNoneNoneNoneNoneNone
James E. UdelsonTufts Medical Center—Chief, Division of CardiologyNoneNoneNoneNoneNoneNoneNone
Clyde W. YancyBaylor University Medical Center—Medical DirectorNoneNoneNoneNoneNoneNoneNone

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

DSMB indicates data safety monitoring board.

  • Writing committee members are required to recuse themselves from voting on sections where their specific relationships with industry may apply.

  • No financial benefit.

  • Significant relationship.